Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Pharma Firms Make Payouts

by Ann M. Thayer
January 18, 2010 | A version of this story appeared in Volume 88, Issue 3

GlaxoSmithKline has exercised an option with ChemoCentryx to license Traficet-EN, a small-molecule CCR9 chemokine receptor antagonist targeting inflammatory bowel diseases. In exchange, ChemoCentryx will get $35 million and possible future milestone payments. Separately, Targacept has received its first payment of $200 million under a collaborative agreement with AstraZeneca. The partners are planning to begin Phase III trials of Targacept’s antidepressant therapy, TC-5214, in mid-2010. Targacept could receive more than $1 billion more in potential milestone payments, though it must give an undisclosed percentage to the University of South Florida Research Foundation.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.